Free Shipping in the U.S. for orders over $1000.  Shop Now>>

CD73 (Immuno-Oncology Target) Antibody [NT5E/4679]

In Stock
Catalog Number Formulation Size Price
4907-MSM9-P0
Purified Ab with BSA and Azide at 200ug/ml
20ug
$229.00
4907-MSM9-P1
Purified Ab with BSA and Azide at 200ug/ml
100ug
$519.00
4907-MSM9-P1ABX
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
100ug
$519.00
Flat Rate Domestic: $75 | Orders outside the US - Contact Us for Order Information | Ships next business day

Applications & Dilutions

Applications Tested Dillution Protocol Note
Immunohistochemistry (IHC)
1-2ug/ml
30 min at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes

Summary

CD73 is a membrane-bound extracellular enzyme overexpressed in several cancer types. Its expression has been linked to poor prognosis in melanoma, colorectal, gastric, triple negative breast cancer, and to a pro-metastatic phenotype in prostate cancer. Together with CD39, it plays a major role in promoting immunosuppression through the pathway degrading adenosine triphosphate (ATP) into adenosine. Within the tumor microenvironment, ATP promotes immune cell-mediated killing of cancer cells. In contrast, adenosine accumulation causes immune suppression, dysregulation of immune cell infiltrates and stimulates angiogenesis resulting in tumor spreading. CD73 is active on the last step of the degradation pathway, where it is the enzyme that actually degrades AMP into adenosine. CD73-blockade promotes anti-tumor immunity by reducing adenosine accumulation. Accordingly, anti-CD73 mAbs stimulate anti-tumor immunity and reduce tumor metastasis in mouse tumor models, and could enhance the efficacy of treatment with anti-PD1 or anti-CTLA4 antibodies.

Product Properties & Targets

Antibody Type
Host
Mouse
Applications
Species Reactivity
Isotype / Light Chain
IgG1 / Kappa
Cellular Localization
Cell surface
Gene Name
Positive Control
A431|Prostate or Lung Carcinoma|U87MG or PC-3 cells. Tonsil
Immunogen
Recombinant full-length human NT5E protein
Alternate Names
5'-nucleotidase, 5'-deoxynucleotidase, Ecto-5'-nucleotidase, IMP-specific 5'-nucleotidase, Thymidylate 5'-phosphatase, 5' NT; 5' nucleotidase (CD73); 5' nucleotidase precursor; 5' nucleotidase, ecto; 5' nucleotidase, ecto (CD73); E5NT; Ecto 5' nucleotidase; Ecto-5'-nucleotidase; eN; eNT; NT; NT5; NT5E; NTE; Purine 5 Prime Nucleotidase

Database Links

Entrez Gene ID
SwissProt

Additional Information

Clone
NT5E/4679
Chromosome Location
6q14.3
Mol. Weight of Antigen
71kDa

Functions

  • Catalyzes the hydrolysis of nucleotide monophosphates, releasing inorganic phosphate and the corresponding nucleoside, with AMP being the preferred substrate (PubMed:21933152, PubMed:34403084, PubMed:24887587, PubMed:22997138, PubMed:23142347). Shows a preference for ribonucleotide monophosphates over their equivalent deoxyribose forms (PubMed:34403084). Other substrates include IMP, UMP, GMP, CMP, dAMP, dCMP, dTMP, NAD and NMN (PubMed:21933152, PubMed:34403084, PubMed:24887587, PubMed:22997138, PubMed:23142347).

Key References

  • Yamashita, Y., et al. 1998. CD73 expression and Fyn-dependent signaling on murine lymphocytes. Eur. J. Immunol. 28: 2981-2990.

Storage & Stability

Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C.Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Limitations

This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Warranty

There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.

Reviews

There are no reviews yet.

Be the first to review “CD73 (Immuno-Oncology Target) Antibody”

Your email address will not be published. Required fields are marked *

PARTNERSHIP OPPORTUNITIES

NeoBiotechnologies holds Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK